We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Expression Analysis Adopts NuGEN’s Ovation™ System

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Expression Analysis Adopts NuGEN’s Ovation™ System "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Expression Analysis, Inc. has announced that it has adopted NuGEN Technologies’ Ovation™ System family of products for amplification, fragmentation and labeling of samples with limited quantities of total RNA for GeneChip microarray analysis.

"Our validation of the Ovation™ System utilized the same RNA samples tested in the Microarray Quality Control Project and employed many of the same analysis methods," commented Dr. Tom Goralski, Senior Director of Laboratory Operations at Expression Analysis.

"Our assessment indicated that the data was excellent and superior in quality relative to that generated using two cycles of in vitro transcription."

"We hope to migrate all of our clients who require microarray testing with limited RNA specimens to this service."

"We will continue to evaluate the Ovation™ System for potential use with whole blood samples."

Expression Analysis, Inc. also announced that it will begin to validate the WT-Ovation™ Pico RNA Amplification System for ultra-small and/or degraded specimens in early October.

"We believe this product may be extremely useful in tumor-based oncology applications," continued Dr. Goralski.

"Adoption of the Ovation™ platform by Expression Analysis speaks to the value of NuGEN’s technology for laboratories involved in high throughput work with valuable and limited samples, especially in the area of oncology research," said Dr. Sue Pandey, Vice President of Commercial Operations at NuGEN Technologies.

"We are extremely pleased to be working with Expression Analysis."